2024-09-02 - Analysis Report
## AMGN Stock Analysis Report

**Company Overview:** Amgen is a leading global biotechnology company focused on discovering, developing, and delivering innovative human therapeutics.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** AMGN: 58.57%, VOO: 89.66%
* **Difference:** -31.09%
* **Relative Divergence:** 46.06% (This means that AMGN's performance is currently at the 46.06% percentile compared to its historical performance difference with VOO.)

**2. Recent Price Action:**

* **Closing Price:** $333.83
* **5-Day Moving Average:** $329.61
* **20-Day Moving Average:** $325.69
* **60-Day Moving Average:** $321.37

**3. Technical Indicators:**

* **RSI:** 68.97 (indicates a slightly overbought condition)
* **PPO:** 0.17 (indicates positive momentum)
* **Delta_Previous_Relative_Divergence:** -12.38 (indicates short-term downward trend)
* **Expected Return:** 7.55% (5-year projected return on current investment)

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Revenue |
|------------|--------|---------|
| 2024-08-07 | 1.39   | 8.39 B$ |
| 2024-05-03 | -0.21  | 7.45 B$ |
| 2023-10-31 | 3.23   | 6.90 B$ |
| 2023-08-04 | 2.58   | 6.99 B$ |
| 2024-08-07 | 2.58   | 6.99 B$ |

The most recent earnings (2024-08-07) showed an EPS of 1.39, exceeding analyst estimates. Revenue also came in strong at 8.39 billion dollars. The company continues to perform well, driven by its strong portfolio of blockbuster drugs.

**5. Overall Analysis:**

AMGN has lagged behind the S&P 500 in recent years, but its current performance is still positive. While the RSI indicates a slightly overbought condition, the positive PPO and strong recent earnings suggest potential for continued growth. However, the negative Delta_Previous_Relative_Divergence signals a short-term downward trend, which may be a cause for concern. The 7.55% expected return, however, suggests potential for long-term growth. Overall, AMGN remains a solid investment with strong fundamentals, though short-term price fluctuations are to be expected.

**6. Key Takeaways:**

* AMGN has underperformed the S&P 500 in recent years but shows signs of potential for continued growth.
* Strong recent earnings and positive momentum indicators suggest future growth prospects.
* Short-term downward trend may impact the stock's price in the immediate future.
* AMGN remains a solid investment with long-term growth potential.